Exane Derivatives’s Northern Trust NTRS Stock Holding History

Exane Derivatives’s Portfolio NTRS Stock Details NTRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,758	Closed	-$159K	–	699
2019 Q1	$159K	Sell	1,758 -233	-12%	-$21K	0.03%	248
2018 Q4	$166K	Hold	1,991	–	–	0.03%	268
2018 Q3	$205K	Sell	1,991 -113	-5%	-$12.1K	0.04%	240
2018 Q2	$220K	Buy	+2,104	New	+$223K	0.04%	252

Other funds holding NTRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exane Derivatives's NTRS Position: Q2 2019 in Review

Exane Derivatives sold out of Northern Trust (NTRS) in Q2 2019, closing a stake of 1,758 shares — an estimated $159K sold.

Exane Derivatives first reported a position in NTRS in Q2 2018 and held it in 4 quarters. The position peaked at $220K in Q2 2018. 624 funds tracked by Wall St. Rank hold NTRS as of Q2 2019.

Exane Derivatives reported no remaining Northern Trust position as of Q2 2019 after selling out during the quarter.
Exane Derivatives sold 1,758 Northern Trust shares in Q2 2019, an estimated $159K.
Exane Derivatives first reported a position in Northern Trust in Q2 2018 and held it in 4 quarters.
Exane Derivatives's Northern Trust position peaked at $220K in Q2 2018.
624 funds tracked by Wall St. Rank held Northern Trust as of Q2 2019.

Based on Exane Derivatives's 13F filing for Q2 2019, filed 12 Jul 2019.